XVARY Composite Score
49
/ 100
Below Average
Combines growth, value, risk, and momentum factors into a single institutional-grade score.
Start here if you're new
What it is
It sells software that drops drug and patient help into doctors' workflow.
How it gets paid
Last year Optimizerx made $109M in revenue. Financial messaging was the main engine at $52M, or 48% of sales.
Why it's growing
Revenue grew 18.8% last year. 74.8% gross margin mattered because it turned a $32.2M quarter into $5.0M of net income.
What just happened
OptimizeRx posted $32.2M in Q4 revenue and $0.51 EPS.
At a Glance
C++ balance sheet — some cracks in the foundation
35/100 earnings predictability — expect surprises
127.8x trailing p/e — you're paying up for this one
0.3% return on capital — nothing to write home about
-$1.10 fy2024 eps est
XVARY composite: 49/100 — below average
What They Do
It sells software that drops drug and patient help into doctors' workflow.
OptimizeRx lives inside doctors' software, so pharma messages land at the point-of-care (the moment a doctor is choosing treatment). Your doctor already has the screen open, which makes the message harder to ignore than a banner ad. With 106 employees, the company does not need to be huge to be sticky.
How They Make Money
$109M
annual revenue · their business grew +18.8% last year
Financial messaging
$52M
Virtual patient support center
$29M
Brand support services
$28M
The Products That Matter
Places pharma messaging in ehr workflows
EHR Channel Network
$109M · effectively the entire business
it generated $109M in revenue last year, but 2026 guidance implies only $109M–$114M. when a one-product company slows, there is nowhere else for the growth story to hide.
75% gross margin
Key Numbers
67.3%
gross margin
For every $100 of sales, $67 stays after direct costs. That is the difference between a business and a money sponge.
$109M
annual revenue
You are buying a company that does nine figures on a $120M market cap. The market is paying about 1.1x sales.
0.3%
capital return
That means $100 invested in the business threw off 30 cents of return. You are not buying a cash machine yet.
$25M
long-term debt
Debt is 17% of capital. That is manageable until revenue stumbles.
Financial Health
C++
Strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 2 — safer than 80% of stocks
- price stability 5 / 100
- long-term debt $25M (17% of capital)
C++ — risk rank looks solid but balance sheet grade needs watching.
Total Return vs. Market
source: institutional data · return history unavailable
What Just Happened
beat estimates
OptimizeRx posted $32.2M in Q4 revenue and $0.51 EPS.
Revenue matched the prior year, gross margin hit 74.8%, and net income reached $5.0M. The quarter was a mix of flat sales and a much fatter margin stack.
$32.2M
revenue
$0.51
eps
74.8%
gross margin
the number that mattered
74.8% gross margin mattered because it turned a $32.2M quarter into $5.0M of net income.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. Plain English, no spam.
Weekly updates
Earnings alerts
Plain English
No spam
What Could Go Wrong
The #1 risk is a premium multiple colliding with a 0–4% revenue guide.
High
Growth premium unwinds
2026 revenue guidance of $109M–$114M implies 0–4% growth after a year that grew 18.8%.
when a stock trades at 127.8x earnings, a growth stall can compress the multiple before revenue even misses.
High
Client concentration
management relies on a concentrated pharmaceutical client base. that is efficient when budgets hold and painful when one large account changes course.
loss of a top client could put roughly $16M–$27M of annual revenue at risk based on the current page's underlying assumptions.
Med
Margin normalization
q4 gross margin reached 75%, but management expects that to move back to the mid-60% range in 2026.
a drop from 75% to 65% on roughly $109M of revenue would remove about $11M of gross profit. that is not a rounding error for a $120M market cap company.
Med
Single-channel exposure
this snapshot shows one revenue engine: the ehr channel network. there is no second segment here to absorb a stumble.
if campaign volume softens inside that channel, the entire $109M revenue line feels it.
a move from 75% gross margin to 65% on a roughly $109M revenue base would cut about $11M from gross profit while the company is guiding only 0–4% growth. that is a lot of pressure for a stock priced on optimism.
Source: institutional data · regulatory filings · risk analysis
Pay Attention To
Metric
Revenue versus the $109M–$114M guide
the whole stock now sits on whether management can do better than the 0–4% range it just gave you.
Trend
Gross margin after the 75% q4 peak
if margins slide into the mid-60% range quickly, the premium software-style framing gets harder to defend.
Calendar
Next earnings report
the next print matters more than usual because investors need to see whether the slowdown was conservatism or a real demand problem.
Risk
Buyback execution against weak growth
the $10M authorization equals about 8% of the market cap. if management buys aggressively, it is signaling confidence. if not, the authorization was just decoration.
Analyst Rankings
earnings predictability
35 / 100
in human-speak, analysts do not see this as a smooth earner. the business can surprise you in either direction.
risk rank
2
this ranking system views the company as safer than most stocks, even though the 5 / 100 price stability says the share price itself can be chaotic.
Source: institutional data
Institutional Activity
institutional ownership data for OPRX is being compiled.
Source: institutional data
Price Targets
3-5 year target range
$14
Current price
Target midpoint · from current
Want the deeper analysis?
The full deep dive: DCF model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
See plans from $5/moThe Deep Dive